Negative regulation of response to type II interferon

Across TCGA pan-cancer cohorts, RNA activity of the Negative regulation of response to type II interferon pathway differs between tumor and matched normal tissue in 9 of the 18 cancer types tested.

The strongest signal is observed in thyroid carcinoma (THCA), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as THCA and LUSC, show the opposite pattern, with lower activity in tumor tissue.

THCA, KIRC, and LUSC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
THCA	Female	III,IV	−0.109	<.001	10	view →
KIRC	Male	IV	+0.042	<.001	9	view →
LUSC	Female	All	−0.102	<.001	8	view →
LUAD	Female	All	−0.058	<.001	7	view →
BRCA	All	III,IV	−0.101	<.001	6	view →
STAD	All	II,III,IV	+0.089	<.001	6	view →
COAD	All	All	−0.034	.001	4	view →
PAAD	All	All	+0.120	.018	2	view →
PRAD	All	All	−0.043	<.001	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 9 strongest of 9 lineages.

GO:0060331–THCA

Open the THCA breakdown →